ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1757

An Economic Systematic Literature Review of Eosinophilic Granulomatosis with Polyangiitis

Scott Doyle1, Emily Moss2, Louise Hartley2, Chris Knight2, Judith Bell2, Outi Ahdesmäki2 and Maebh Kelly3, 1Value Evidence and Outcomes, GlaxoSmithKline, London, United Kingdom, 2RTI Health Solutions, Manchester, United Kingdom, 3Pope Woodhead, London, United Kingdom

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Churg-Strauss syndrome, Economics, monoclonal antibodies and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Vasculitis – ANCA-Associated Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: To better understand the available economic evaluations in eosinophilic granulomatosis with polyangiitis (EGPA), a systematic literature review was undertaken. The primary objective of this review was to collect economic evidence including economic evaluations and models, cost-utility analyses, utility studies, and prospective and retrospective studies reporting costs or resource utilisation for patients treated for EGPA. Secondary objectives were to explore the natural history of EGPA.

Methods: The review was undertaken to meet the requirements of the National Institute for Health and Care Excellence (NICE), the Centre for Reviews and Dissemination’s Guidance for Undertaking Reviews in Health Care, the Cochrane Collaboration, and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting methods. Searches were conducted in electronic databases (PubMed, Embase, Cochrane, BIOSIS, Econlit); conference abstracts (ISPOR; EULAR; ACR), and key international health technology assessment websites. Searches were not limited by date, language, or geographical location. Quality assessments were conducted on economic evaluations using the Drummond checklist in line with NICE requirements. Quality assessments were not conducted for other types of economic evidence.

Results:

The databases yielded a total of 2,055 titles (439 duplicates), internet searches yielded 335, and hand-searching 12. After initial screening of abstracts, a total of 294 publications were progressed for further screening leaving 85 articles deemed acceptable for data extraction. Of the 85 studies identified:

  • Only a single economic evaluation was identified which had limited applicability to the research question as it focused on the cost-effectiveness of pneumonia prophylaxis in Wegener’s granulomatosis (WG);
  • 31 studies reported health related quality of life or symptom burden outcomes (17 reported SF-36 Health Survey (SF-36), 4 reported Health Assessment Questionnaire (HAQ) outcomes, and 1 reported EQ-5D outcomes);
  • 22 reported cost and resource-use outcomes (14 studies reported medication usage, 9 studies reported productivity lost, 4 studies reported on impact of disease on income, 3 studies reported resource use, 2 reported overall cost, and 1 study reported medication costs);
  • 45 natural history studies were identified (18 reported the outcome ‘achieved remission’, and 26 reported relapse rates. 34 of the studies reported all-cause mortality; 14 studies reported EGPA-related mortality).

Conclusion: This systematic literature review has identified many gaps in the literature regarding EGPA and its treatments, particularly in economic evaluations. This is perhaps not surprising, given that EGPA is a rare disease with limited treatment options. Of the studies identified there was a considerable amount of heterogeneity. The lack of standardised data collection methods makes the synthesis of economic evidence in EGPA challenging.


Disclosure: S. Doyle, GlaxoSmithKline, 1, 3; E. Moss, None; L. Hartley, None; C. Knight, None; J. Bell, None; O. Ahdesmäki, None; M. Kelly, GlaxoSmithKline, 3.

To cite this abstract in AMA style:

Doyle S, Moss E, Hartley L, Knight C, Bell J, Ahdesmäki O, Kelly M. An Economic Systematic Literature Review of Eosinophilic Granulomatosis with Polyangiitis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/an-economic-systematic-literature-review-of-eosinophilic-granulomatosis-with-polyangiitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-economic-systematic-literature-review-of-eosinophilic-granulomatosis-with-polyangiitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology